Evidence map›Paper›PMID 40844633›Full record

ReviewJournal of cancer research and clinical oncology2025

Research and development prospects of TRIM65.

Nian-Hua Deng, Jie-Hai Chen, Zhen Tian, Shou-Bo Quan

Abstract readReview
In one paragraph

Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nian-Hua Deng *The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, People's Republic of China.
Jie-Hai Chen *Dongguan Maternal and Child Health Care Hospital, Dongguan, 523125, Guangdong, People's Republic of China.
Zhen TianThe Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, People's Republic of China.
Shou-Bo QuanThe Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, People's Republic of China. shouboquan@163.com.

Funding

Special Project for Clinical and Basic Sci &Tech Innovation of Guangdong Medical University GDMULCJC2024122
6 · The paper itself

Abstract

Ubiquitination, the prevalent posttranslational modification, plays a crucial role in regulating protein function, localization, and degradation within cellular environments. As an E3 ubiquitin ligase, TRIM65 has been shown in various studies to facilitate the ubiquitination of specific substrates, thereby controlling inflammation, innate immune responses, cell proliferation, apoptosis, and tumor progression. Given the multifaceted and significant role of TRIM65, this review compiles existing research on TRIM65 and lays the groundwork for future studies aimed at uncovering the mechanisms of TRIM65. Further understanding of TRIM65's interactions with its substrate proteins will offer valuable insights into the molecular underpinnings of certain diseases. Additionally, by identifying small molecules or inhibitors that target TRIM65, we may be able to develop novel drugs that modulate its activity. Such research could lead to more precise and effective treatments for conditions such as chronic inflammation, autoimmune diseases, and cancer. In summary, the study of TRIM65 not only enhances our understanding of fundamental cellular processes but also opens up new perspectives and avenues for the development of innovative therapies.

Indexed as

NeoplasmsTripartite Motif ProteinsUbiquitin-Protein LigasesAnimalsHumansInflammationUbiquitinationTRIM65 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesCancerInflammationTargeted protein degradationTRIM65Ubiquitination

Identifiers

PMID40844633
PMCPMC12373630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.